Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 18 04:00PM ET
132.89
Dollar change
+0.52
Percentage change
0.39
%
Index- P/E49.19 EPS (ttm)2.70 Insider Own0.00% Shs Outstand3.38B Perf Week1.26%
Market Cap449.62B Forward P/E32.22 EPS next Y4.12 Insider Trans- Shs Float3.38B Perf Month9.15%
Income12.14B PEG17.57 EPS next Q0.78 Inst Own9.15% Short Float0.14% Perf Quarter35.60%
Sales33.70B P/S13.34 EPS this Y25.41% Inst Trans-2.72% Short Ratio0.96 Perf Half Y39.57%
Book/sh4.67 P/B28.47 EPS next Y21.19% ROA29.90% Short Interest4.88M Perf Year91.36%
Cash/sh1.32 P/C100.37 EPS next 5Y2.80% ROE87.44% 52W Range67.66 - 138.28 Perf YTD28.46%
Dividend Est.1.67 (1.26%) P/FCF37.29 EPS past 5Y16.48% ROI64.47% 52W High-3.90% Beta0.41
Dividend TTM1.03 (0.77%) Quick Ratio0.64 Sales past 5Y14.25% Gross Margin84.60% 52W Low96.41% ATR (14)3.36
Dividend Ex-DateMar 22, 2024 Current Ratio0.82 EPS Y/Y TTM56.16% Oper. Margin44.12% RSI (14)61.96 Volatility2.02% 2.02%
Employees63370 Debt/Eq0.25 Sales Y/Y TTM34.77% Profit Margin36.04% Recom2.03 Target Price131.47
Option/ShortYes / Yes LT Debt/Eq0.19 EPS Q/Q71.63% Payout36.04% Rel Volume0.76 Prev Close132.37
Sales Surprise4.87% EPS Surprise6.77% Sales Q/Q44.01% EarningsJan 31 BMO Avg Volume5.06M Price132.89
SMA204.69% SMA5012.86% SMA20035.45% Trades Volume3,898,758 Change0.39%
Date Action Analyst Rating Change Price Target Change
Jan-23-24Initiated Morgan Stanley Overweight $120
Jan-16-24Resumed UBS Neutral
Dec-01-23Initiated Cantor Fitzgerald Overweight $120
Oct-02-23Initiated Argus Buy $110
Jul-14-23Initiated HSBC Securities Buy
Jul-15-22Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-28-22Downgrade UBS Neutral → Sell
Jun-27-22Upgrade Exane BNP Paribas Underperform → Neutral
Jun-07-22Upgrade JP Morgan Neutral → Overweight
May-31-22Upgrade Guggenheim Neutral → Buy
Today 07:30AM
05:50AM
03:00AM
Mar-18-24 05:50PM
10:18AM
10:05AM Loading…
10:05AM
09:30AM
Mar-17-24 02:28PM
09:46AM
09:00AM
08:50AM
05:00AM
Mar-16-24 05:00AM
Mar-15-24 01:38PM
12:44PM
11:16AM Loading…
11:16AM
10:18AM
10:15AM
09:50AM
07:46AM
05:50AM
Mar-14-24 09:38AM
05:15AM
Mar-13-24 12:40PM
05:03AM
01:00AM
Mar-12-24 08:31PM
04:53PM
03:13PM
12:00PM
12:00PM Loading…
12:00PM
11:34AM
10:28AM
09:30AM
08:53AM
07:45AM
05:00AM
Mar-11-24 05:50PM
12:44PM
10:33AM
09:45AM
08:46AM
07:23AM
06:59AM
06:47AM
Mar-10-24 09:29AM
05:00AM
04:33AM
Mar-09-24 04:47PM
Mar-08-24 05:31PM
04:52PM
04:39PM
04:25PM
03:46PM
03:24PM
02:58PM
02:57PM
02:18PM
01:58PM
01:42PM
01:16PM
01:07PM
11:39AM
11:28AM
10:58AM
10:27AM
10:03AM
08:51AM
07:15AM
07:14AM
07:11AM
06:09AM
06:03AM
05:51AM
05:35AM
04:29AM
04:04AM
Mar-07-24 09:12PM
06:14PM
04:12PM
04:04PM
02:23PM
02:00PM
01:24PM
12:05PM
12:04PM
12:00PM
11:51AM
11:49AM
11:45AM
11:42AM
11:31AM
11:21AM
11:16AM
10:41AM
10:31AM
10:31AM
10:19AM
10:15AM
10:10AM
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.